Business Wire

BACARDI

25.3.2020 18:38:07 CET | Business Wire | Press release

Share
From USA to France and From UK to Mexico, Bacardi Diverts Global Production to Increase Hand Sanitizer Supply for Local Communities

Family-owned Bacardi has expanded its commitment across countries and brands to help produce more than 267,000 gallons (1.1 million liters) of hand sanitizers, as worldwide demand continues to exceed supply in efforts to reduce the risk of COVID-19. This week, eight Bacardi-owned manufacturing sites across the United States, Mexico, France, England, Italy and Scotland are joining the efforts, following last week’s announcement that Bacardi in Puerto Rico would supply alcohol to make hand sanitizers. Across the sites, Bacardi is diverting its global production power, resources and processes to supply the much-needed alcohol essential for the increased production of hand sanitizers.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200325005615/en/

Bacardi is also playing a part in donating these products to local organizations and emergency responders, as well as its employees and contractors. In addition, the company is providing alcohol at cost to select partner companies looking to ramp up their production of hand sanitizers for commercial sale. These temporary, emergency actions at all locations will not disrupt the supply of brands in the Bacardi portfolio.

“Over our 158-year history, we have risen to many challenges and we are doing the same again in response to COVID-19,” said Jean-Marc Lambert, SVP Global Operations for Bacardi. “All our brands and partners involved in this initiative will help people most in need benefit from the supply of these hand sanitizers. Our goal is to make a very real difference in the fight against COVID-19.”

The current list of sites providing support either immediately or in the coming week are:

  • BACARDÍ rum in Puerto Rico – partnered with Puerto Rico based manufacturer Olein Refinery to provide raw materials that will enable the production of more than 1.7M units of 10-ounce (300 ml) hand sanitizers. Donated product to local USPS, firefighters, police and non-profit Somos Unidos (United Way);
  • Bacardi Bottling Corporation in Jacksonville, FL, USA – is planning to help produce approximately 23,000 gallons (87,000 liters) to make 120,000 units of 25-ounce (750 ml) bottles hand sanitizer for donation to local hospitals, firefighters and police. In addition, the team will supply 7,600 gallons (29,000 liters) to nearby manufacturers.
  • BACARDÍ rum in Tultitlán, Mexico – supplying more than 5,200 gallons (20,000 liters) of alcohol to nearby manufacturer, Grupo Sterk, to help increase production of hand sanitizer by approximately 6,300 gallons (24,000 liters), of which 2,100 gallons (8,000 liters) will be donated by Bacardi to local communities in Tultitlán, Arandas and Atotonilco;
  • GREY GOOSE® vodka in Cognac, France – will supply 7,600 gallons (29,000 liters) of alcohol per day to French companies to increase supply of hand sanitizers by 9,500 gallons (36,000 liters) for local pharmacies, hospitals and the emergency services;
  • BOMBAY SAPPHIRE® gin in Hampshire, England – is helping to produce a small quantity of hand sanitizers that will be donated to local doctors, chemists and care homes;
  • MARTINI in Pessione, Italy – is supplying alcohol for the production of 1,000 7-ounce (200ml) hand sanitizers for the local community, Red Cross and local emergency services;
  • DEWAR’S® Blended Scotch Whisky in Aberfeldy, Scotland – is helping to produce a small quantity of hand sanitizers for the Scottish Ambulance Association among other local community groups;
  • ANGEL’S ENVY® Kentucky Straight Bourbon in Louisville, KY, USA – is supplying nearly 1,000 gallons (3,800 liters) of alcohol to create approximately 16,000 8-ounce (250 ml) bottles of free hand sanitizers for first responders and healthcare professionals.

All hand sanitizers produced in collaboration with Bacardi contain more than the minimum alcohol content recommended by the World Health Organization for containing the spread of the virus.

About Bacardi

The Bacardi Limited brand portfolio comprises more than 200 brands and labels, including BACARDÍ® rum, GREY GOOSE® vodka, PATRÓN® tequila, DEWAR’S® Blended Scotch whisky, BOMBAY SAPPHIRE® gin, MARTINI® vermouth and sparkling wines, CAZADORES® 100% blue agave tequila, and other leading and emerging brands including WILLIAM LAWSON’S® Scotch whisky, ST-GERMAIN® elderflower liqueur, and ERISTOFF® vodka. Founded more than 158 years ago in Santiago de Cuba, family-owned Bacardi Limited currently employs more than 7,000, operates production facilities in 11 countries, and sells its brands in more than 170 countries. Bacardi Limited refers to the Bacardi group of companies, including Bacardi International Limited. Visit www.bacardilimited.com or follow us on Twitter , LinkedIn or Instagram .

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte Announces Positive CHMP Opinion for Zynyz® (retifanlimab) for First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)30.1.2026 15:29:00 CET | Press release

Pending the European Commission decision, Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) will be the first PD-1 immunotherapy treatment for patients with advanced squamous cell carcinoma of the anal canal (SCAC) in EuropeGlobally, the prevalence of SCAC is estimated at around 1 or 2 cases per 100,000 people, with a higher incidence in women than in men1,2,3The Committee for Medicinal Products for Human Use (CHMP) positive opinion is based on data from the Phase 3 POD1UM-303/InterAACT2 trial which showed patients with advanced SCAC achieved significantly improved progression-free survival with Zynyz in combination with carboplatin and paclitaxel as a first-line treatment4 Incyte (Nasdaq:INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (

Mediawan to Acquire The North Road Company, Creating a New Global Independent Content Platform30.1.2026 13:32:00 CET | Press release

Mediawan, the leading independent European studio led by Pierre-Antoine Capton, co-founded by Capton, Xavier Niel and Matthieu Pigasse, today announced the signing of an agreement to acquire The North Road Company (“North Road”), the preeminent independent U.S.-based studio founded by Peter Chernin. The combination creates one of the world’s largest independent studios with major creative hubs in the five continents and capabilities spanning all genres, formats and audiences. Together, Mediawan and North Road will have a stronger ability to accelerate the development of powerful IP, foster fresh creative synergies through format adaptations and co-production opportunities, and deliver ever greater value to viewers, talent and partners worldwide. The acquisition brings together two of the most dynamic independent studios in the sector with world-class creative talent, premium IP, and the scale to deliver content at the highest level. In an industry undergoing significant consolidation,

BrightSign Powers Intelligent Signage Experiences at ISE 202630.1.2026 09:00:00 CET | Press release

The Latest Players and AI Capabilities Drive Captivating, Personalized, and Interactive Signage With more industries embracing the power of visual storytelling, BrightSign, the provider of the most advanced, capable, and trusted digital media players and operating system, will showcase the latest developments in digital signage technology at ISE 2026 in Barcelona, Spain from February 3-6, 2026. BrightSign’s latest innovations come to life at booth #4S-150 through interactive real-world demos featuring retail, QSR, transportation, and corporate use cases. Visitors can test new AI-powered object detection capabilities of BrightSign players, allowing them to pick up an object and see the content on the screen respond immediately. Booth activations will be powered by BrightSign’s reliable platform including bsn.Control, BrightSignOS™, brightAuthor connected, and its global partner ecosystem. “In today’s immersive, personalized and visual world, the stakes have never been higher for powerfu

Candela Ushers in a New Era of Aesthetic Innovation at IMCAS Paris With the Launch of the Glacē™ System30.1.2026 08:30:00 CET | Press release

Iconic Vbeam® Pro and Matrix™ Systems showcased ahead of broader commercial availability Candela, a global leader in energy-based aesthetic technologies, today announced the European launch of the Glacē™ System, a facial treatment platform that signals a bold new chapter for the company and the future of aesthetic medicine. In addition to the launch of the Glacē System, Candela will also showcase its Matrix system for radiofrequency-based skin renewal and its iconic Vbeam® Pro vascular treatment platform at IMCAS 2026. Both Matrix and VBeam Pro platforms are currently available in select EMEA markets and are expected to be comprehensively launched shortly, further strengthening Candela’s leadership in the energy-based device market. Unveiled at the IMCAS World Congress 2026, these launches underscore Candela’s continued commitment to delivering innovative, science-backed treatment solutions for high-demand patient needs. Candela leads the industry in clinical efficacy and safety, suppo

Merz Therapeutics Appoints Dan Staner as President, Region Europe30.1.2026 08:00:00 CET | Press release

Merz Therapeutics today announced the appointment of Dan Staner as President, Region Europe, effective February 1, 2026. In this role, Dan will oversee the company’s European business and drive regional growth. Dan will report directly to Merz Therapeutics Chief Executive Officer, Stefan König, and will join the Therapeutics Executive Team. His appointment reflects the company’s continued commitment to strengthening its leadership capabilities and accelerating its growth strategy across key European markets.​ “Dan brings a strong track record of building and scaling biopharmaceutical businesses across Europe,” said Stefan König, CEO of Merz Therapeutics. “His deep commercial, strategic, and regional leadership experience will be instrumental in advancing our growth ambitions, expanding patient access to our therapies, and further strengthening our presence in Europe. We are very pleased to welcome Dan to Merz Therapeutics.”​ Throughout his career, Dan has held senior leadership roles i

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye